Search for Clinical Trial Results
Ewing Sarcoma - 29 Studies Found
Status | Study |
Terminated |
Study Name: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Condition:
Date: 2012-05-31 Interventions: Drug: Mithramycin Phase I Portion: Mithramycin will be administered in escalating doses to children and |
Completed |
Study Name: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma Condition: Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) Date: 2013-06-10 Interventions:
|
Completed |
Study Name: Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors Condition:
|
Completed |
Study Name: Study of Tumor Samples From Patients With Ewing Sarcoma Condition: Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Date: 2009-05-09 Interventions: Other: laboratory biomarker analysis Correlative studies |
Completed |
Study Name: Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults Condition:
Date: 2013-01-23 Interventions: Other: MRI MRI exam will be performed in all patients incl |
RECRUITING |
Study Name: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Condition: Ewing Sarcoma Date: 2024-05-19 Interventions: Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles.If still on study therapy the participants will con |
RECRUITING |
Study Name: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Condition: Refractory Ewing Sarcoma Date: 2024-05-19 Interventions: Administered as intravenous (IV) infusion once every 3 weeks (Q3W) |
RECRUITING |
Study Name: Lurbinectedin in FET-Fused Tumors Condition: Ewing Sarcoma Date: 2024-05-19 Interventions: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days.Doses will be determined in the phase 1 portion of the trial. |
COMPLETED |
Study Name: Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. Condition: Ewing Sarcoma of Bone Date: 2024-05-19 Interventions: . TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only act |